FDA calendar · June 2023 · built from SEC filings

PDUFA dates June 2023: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

0 PDUFA dates fell in June 2023. The FDA calendar also recorded 32 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in June 2023

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

June 2023: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
Jun 2023Month disclosedMethotrexate Preservative Free (methotrexate)ALDXComplete Response Letterprimary vitreoretinal lymphomaCRL issuedSEC Form 8-K
June 5, 2023Prevymis (letermovir)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
June 8, 2023Beyfortus (nirsevimab-alip)AZNAdvisory committee—PositiveFDA advisory committee calendar
June 12, 2023LINZESS® (linaclotide)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
June 14, 2023Abrilada (adalimumab-afzb)PFELabel expansion—ApprovedopenFDA Drugs@FDA
June 15, 2023Camzyos® (mavacamten)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
June 15, 2023Triumeq Pd (abacavir sulfate; dolutegravir sodium; lamivudine)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
June 20, 2023BLINCYTO® (blinatumomab)AMGNLabel expansion—ApprovedopenFDA Drugs@FDA
June 20, 2023Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)ARGXFDA approval—ApprovedopenFDA Drugs@FDA
June 20, 2023Talzenna (talazoparib tosylate)PFELabel expansion—ApprovedopenFDA Drugs@FDA
June 22, 2023RINVOQ® (upadacitinib)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
June 23, 2023Litfulo (ritlecitinib tosylate)PFEFDA approvalTo treat severely patchy hair lossApprovedFDA Novel Drug Approvals
June 27, 2023Cyclophosphamide (cyclophosphamide)BAXFDA approval—ApprovedopenFDA Drugs@FDA
June 27, 2023Ngenla (somatrogon-ghla)PFEFDA approvalTo treat growth failure due to inadequate secretion of endogenous growth hormoneApprovedFDA Novel Drug Approvals
June 27, 2023PAVBLU® (aflibercept)REGNComplete Response Letter—CRL issuedFDA Complete Response Letters
June 28, 2023Simlandi (adalimumab-ryvk)ALVOComplete Response Letter—CRL issuedFDA Complete Response Letters

June 2023: dated readouts

DateDrugCompanyEventIndicationStatusSource
Jun 2023Month disclosed—ALZNTopline readout—Positivesec_s1
Jun 2023Month disclosed—GMABTopline readout—PositiveSEC Form 10-K
Jun 2023Month disclosed—MLTXTopline readout—PositiveSEC Form 10-K
Jun 2023Month disclosed—MLTXTopline readoutmoderate-to-severe HSMet primary endpointSEC Form 10-Q
Jun 2023Month disclosedOpdivo® (nivolumab)SLSTopline readout—Positivesec_424b
Jun 2023Month disclosedSCI-110SPRCTopline readoutAlzheimer's disease and agitationPositiveSEC Form 10-K
June 13, 2023lanifibranor (IVA337)IVATopline readoutNAFLD and T2DPositivesec_424b
June 26, 2023EP-104EPRXTopline readout—PositiveSEC 8-K Exhibit 99.1
June 29, 2023IGALMI® (dexmedetomidine)BTAIQTopline readout—PositiveSEC Form 10-Q

June 2023: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Jun 2023Month disclosedluveltaSTROTrial startplatinum-resistant ovarian cancer in June 2023CompletedSEC Form 10-Q
Jun 2023Month disclosedXYNGARIDRMATrial start—CompletedSEC Form 10-K
June 6, 2023urcosimod (OK-101)OKYOTrial start—Completedsec_424b
June 13, 2023lanifibranor (IVA337)IVATrial startNAFLD and T2DCompletedsec_424b
June 26, 2023IPH5201IPHATrial start—CompletedSEC Form 10-K
June 22, 2023LB-100NMADTrial start—CompletedSEC Form 10-Q
June 30, 2023imeroprubart (IMVT-1402)IMVTTrial start—CompletedSEC Form 10-Q

Questions

What PDUFA dates are in June 2023?

0 PDUFA dates fell in June 2023. The FDA calendar also recorded 32 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.